Jefferies Starts Valeant Pharmaceuticals (VRX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- HSBC Downgrades IBM (IBM) to Reduce, 'Stretched Valuation'
TD Securities Upgrades Valeant Pharmaceuticals (VRX) to Buy
April 23, 2014 7:23 AM EDTTD Securities upgraded Valeant Pharmaceuticals (NYSE: VRX) from Hold to Buy with a price target of $160.00 (from $145.00). The change follows news it is teaming with Bill Ackman to acquire Allergan.
Analyst Lennox Gibbs said, "The proposed transaction could substantially... More
